QBiotics gains FDA orphan drug designation for cancer treatment proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
BRISBANE, Australia, May 31, 2023 /PRNewswire/ QBiotics Group Limited (QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticalsis pleased to announce that Richard Godfrey will present to potential partners and investors at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through June 2023. Mr Godfrey, representing QBiotics in Business Development, Licensing and Partnerships, will provide an update on the Company's human and veterinary programmes in oncology and wound healing. The presentations will include recent phase I safety and efficacy data with Tigilanol tiglate (TT) in cancer patients and details of two ongoing phase II studies in later stage patients with Head and Neck cancer and Soft Tissue Sarcoma, being treated with TT. The Sachs 9th Annual Immuno-Oncology Innovation Forumfor Business Development, Licensing and investment is at the
/PRNewswire/ DelveInsight s Soft Tissue Sarcoma Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline.
The prevalence of soft tissue sarcoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of soft tissue sarcoma and the